Science News — Clinical Science: Special Reports 2014

Scientific Sessions 2014

November 15–19, 2014
Chicago, Illinois

Monday's Clinical Science: Special Reports

Timothy J. Gardner, MD, moderator, and Mikhail N. Kosiborod, MD, one of the presenters, review the science on the program for CS.03 Management of Cardiovascular Disease.

Impact of a Multidisciplinary Management Program on Recurrent Hospitalization and Mortality in Older Individuals With Chronic Atrial Fibrillation: A Multicentre Randomized Trial
Simon Stewart | Baker IDI Heart and Diabetes Institute Melbourne, Victoria, Australia

Efficacy and Safety of ZS-9 in Patients with Hyperkalemia: Results from the HyperkAlemia RandoMized interventiON multI-dose ZS-9 maintEnance (HARMONIZE) Clinical Trial
Mikhail Kosiborod | Saint Luke's Mid America Heart Institute Kansas City, MO

Impact of Additive Use of Olmesartan in Patients With Chronic Heart Failure: The Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT) Trial
Yasuhiko Sakata | Tohoku University Sendai, Japan

Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor PCC
Hamim Zahir | Daiichi Sankyo Pharma Development Edison, NJ

ANNEXA™-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors
Mark Crowther | McMaster University Hamilton, ON, Canada

Gregg C. Fonarow, MD and Clyde Yancy, MD, MSci, moderators of CS.02 Off the Beaten Pathologies, review the science presented at that session.

The Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor (ARNI) With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial
John JV McMurray | University of Glasgow Glasgow, United Kingdom

PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Infusion of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI
Arshed A Quyyumi | Emory University Atlanta, GA

Ventricular Functional Response to Spinal Cord Stimulation for Advanced Heart Failure: Primary Results of the Randomized Defeat-HF Trial
Douglas P Zipes | Indiana University School of Medicine Indianapolis, IN

Efficacy of Left Ventricular Augmentation With Algisyl-LVR in the Treatment of Advanced Heart Failure Patients With Ischemic and Non-Ischemic Cardiomyopathy: Results of the AUGMENT-HF Multicenter Randomized Controlled Trial
Douglas L Mann | Washington University School of Medicine, Barnes Jewish Hospital St. Louis, MO

Tuesday's Clinical Science: Special Reports

Mark Link, MD, and Mintu Turakhia, MD, MAS, two of the discussants in CS.04 , discuss the results presented in the session for The MagnaSafe Registry and Intention-to Tweet.

High-Density Lipoprotein Cholesterol Efflux Capacity is Associated With Incident First Atherosclerotic Cardiovascular Events in the Multi-Ethnic, Population-Based Dallas Heart Study
Anand Rohatgi | University of Texas Southwestern Medical Center Dallas, TX

A Cluster Randomized Controlled Trial to Evaluate The Effect of a Simplified Multifaceted Management Program in High Cardiovascular Disease Risk Patients in Rural China and India: Simcard Study
Maoyi Tian | The George Institute for Global Health Beijing, China

Intention-to-Tweet: A Randomized Trial of Social Media from Circulation
Caroline Fox | Circulation Journal Boston, MA

Determining the Risks of Magnetic Resonance Imaging at 1.5 Tesla for Patients with Non-MRI Conditional Pacemakers and Implantable Cardioverter Defibrillators: Final Results of The MagnaSafe Registry
Robert J Russo | Scripps Clinic La Jolla, CA

Frederick Masoudi, MD and Michael Farkouh, MD review the highlights of the science presented in CS.01 Updates on Randomized Trials.

On-Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
Michael A Blazing | Duke Clinical Research Institute | Durham, NC

Lifetime Clinical and Economic Benefits of Statin-Based LDL Lowering in the 20-Year Follow-up of the West of Scotland Coronary Prevention Study
Chris J Packard | University of Glasgow | Glasgow, United KingdomPresentation Slides (PDF)

Regional Analysis of Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)
Marc Pfeffer | Brigham & Women's Hospital | Boston, MA

Comparison of Ischemic and Bleeding Events After Drug-Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy Study
Dean J Kereiakes | The Christ Hospital Heart and Vascular Center/The Lindner Research Center | Cincinnati, OH

Wednesday's Clinical Science: Special Reports

David Goff Jr., MD, PhD, and Amit Khera, MD discuss the science presented in CS.05 on the Results of ODYSSEY.

Efficacy and Safety of Combining Alirocumab With Atorvastatin or Rosuvastatin versus Statin Intensification or Adding Ezetimibe in High Cardiovascular Risk Patients: ODYSSEY OPTIONS I and II
Harold Bays | Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY

State of the Art: The Odyssey Trials
Amit Khera | University of Texas Southwestern Medical Center, Dallas, TX

ODYSSEY HIGH FH: Efficacy and Safety of Alirocumab in Patients With Severe Heterozygous Familial Hypercholesterolemia
Henry N Ginsberg | Columbia University College of Physicians and Surgeons, New York, NY

Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Suboptimally Controlled Hypercholesterolemia on Maximally Tolerated Doses of Statins: The ODYSSEY COMBO I Study
Dean J Kereiakes | The Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati, OH

Long-term Safety, Tolerability and Efficacy of Alirocumab versus Placebo in 2,341 High Cardiovascular Risk Patients: ODYSSEY LONG TERM
Jennifer G Robinson | University of Iowa, Iowa City, IA

Challenges of Surrogate Outcomes
Michael Pencina | Duke Clinical Research Institute, Durham, NC